Michael Keller

2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy

Diastolic dysfunction in hypertrophic cardiomyopathy. Effect on active force generation during systole.

Disopyramide in hypertrophic cardiomyopathy II. Noninvasive assessment after oral administration

American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines

Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence

Disopyramide in hypertrophic cardiomyopathy I. Hemodynamic assessment after intravenous administration

ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities

Hypertrophic cardiomyopathy

Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy

Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases

Hypertrophic Cardiomyopathy

Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005)

A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy

Calcium-Antagonist Receptors in the Atrial Tissue of Patients with Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy

Comparison of the effects of nitroprusside and nifedipine on diastolic properties in patients with hypertrophic cardiomyopathy: Altered left ventricular loading or improved muscle inactivation?

Effects of verapamil on haemodynamic function and myocardial metabolism in patients with hypertrophic cardiomyopathy.

Hemodynamic effects of verapamil in children and adolescents with hypertrophic cardiomyopathy.

Use of calcium-channel blocking drugs in hypertrophic cardiomyopathy

Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review

Prognosis in hypertrophic cardiomyopathy: Role of age and clinical, electrocardiographic and hemodynamic features

2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy

Verapamil therapy: A new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration

The natural history of idiopathic dilated cardiomyopathy

2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death

Long-term Clinical and Echocardiographic Follow-up After Surgical Correction of Hypertrophic Obstructive Cardiomyopathy With Extended Myectomy and Reconstruction of the Subvalvular Mitral Apparatus

Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy. Double-blind crossover study.

Effects of nifedipine and propranolol combined therapy in patients with hypertrophic cardiomyopathy

Chronic verapamil therapy in pediatrie and young adult patients with hypertrophic cardiomyopathy

Effects of sublingual nifedipine on hemodynamics and systolic and diastolic function in patients with hypertrophic cardiomyopathy.

ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities

Mechanisms of Diabetic Complications

Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies

Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy.

Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy.

Effects of verapamil on left ventricular systolic and diastolic function in patients with hypertrophic cardiomyopathy: pressure-volume analysis with a nonimaging scintillation probe.

Prevalence of Hypertrophic Cardiomyopathy in a General Population of Young Adults

Comparative pharmacology of calcium antagonists: Nifedipine, verapamil and diltiazem

Regional left ventricular asynchrony and impaired global left ventricular filling in hypertrophic cardiomyopathy: Effect of verapamil

The frontiers of cardiomyopathy.

Molecular Mechanisms of Myocardial Remodeling

Calcium Channel Blocking Agents in the Treatment of Cardiovascular Disorders. Part II: Hemodynamic Effects and Clinical Applications

Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects.

Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects.

Blood flow to primary tumors and lymph node metastases in SMT-2A tumor-bearing rats following intravenous flunarizine.

Treatment of Cardiomyopathies

Management of Symptoms in Hypertrophic Cardiomyopathy

Treatment of hypertrophic obstructive cardiomyopathy with verapamil.

Calciumantagonistische Therapie bei hypertroph-obstruktiver Kardiomyopathie